World Diabetes Day is November 14 because it marks Frederick Banting's birthday. He was born on November 14, 1891, and helped discover insulin, a chemical messenger that helps control blood sugar. The observance honors that work while keeping attention on people living with diabetes today.

Why is World Diabetes Day November 14?

The Nobel Foundation's record gives Banting's birth date as “14 November 1891.” The campaign's own history confirms that his birthday is the reason for choosing November 14.

Our history of the 1923 Nobel Prize for insulin follows the discovery and the award. The awareness day came decades later.

December 20, 2006: the document behind UN recognition

The United Nations General Assembly adopted Resolution 61/225 on December 20, 2006. Its heading reads “Resolution adopted by the General Assembly on 20 December 2006.”

A separate line at the top says “18 January 2007,” the document's distribution date. The resolution designated November 14 as a United Nations Day, with annual observance beginning in 2007.

The day before: a campaign already 15 years old

On December 19, 2006, World Diabetes Day already existed. The International Diabetes Federation, or IDF, had established it in 1991 with support from the World Health Organization, or WHO.

WHO's history of the campaign describes its origins in growing concern about diabetes' health and economic effects. The UN resolution itself acknowledges the campaign's work since 1991.

What the resolution changed

The resolution invited governments, health organizations and community groups to raise awareness through education and public communication. It also encouraged countries to develop policies for diabetes prevention, treatment and care.

That widened the focus beyond remembering a discovery. It put the continuing work of health systems alongside the anniversary.

That wider view matters for someone prescribed a medicine such as semaglutide today. A medicine sits within a care plan that also includes understanding the condition, checking progress and keeping access to follow-up. An awareness campaign can draw attention to those needs; the individual care plan still belongs with a clinician.

What happened next: 2007, 2017 and 2021

2007: the UN observance began. November 14 continued as the annual date. The campaign's birthday connection remained the same as its international recognition grew.

2017: semaglutide trial evidence. The SUSTAIN 1 trial in The Lancet Diabetes & Endocrinology compared semaglutide with placebo, a treatment without the active medicine. It followed adults with type 2 diabetes, a condition in which the body has trouble using insulin properly. Over 30 weeks, it tracked blood sugar, body weight and side effects.

These participants had previously managed their condition with diet and exercise alone. That detail matters when placing the trial in the history of diabetes care.

2021: a different hormone-based medicine. The SURPASS-2 trial in the New England Journal of Medicine compared tirzepatide with semaglutide over 40 weeks in people with type 2 diabetes.

Semaglutide copies the action of GLP-1, a gut hormone, or chemical messenger. Tirzepatide acts on both GLP-1 and GIP signals. GIP is another gut hormone involved in the insulin response. These gut hormones are called incretins; our incretin guide explains how they work.

Those studies belong to a later chapter than Banting's work. They tested different medicines in defined patient groups, with their own benefits and risks to assess.

2021–2022: goals for access to care

WHO launched the Global Diabetes Compact in April 2021 to improve prevention and care, particularly in lower-income countries. Its diabetes fact sheet records that milestone and five global coverage targets adopted in May 2022.

One target is diagnosing 80% of people with diabetes by 2030. Another is access to affordable insulin and blood sugar monitoring for everyone with type 1 diabetes, which involves too little insulin production. WHO lists those targets alongside its current campaign.

November 2026: early action on diabetes

As of November 12, 2026, the day this article was written, WHO's 2026 theme is “Early action on diabetes.” Its priorities include earlier diagnosis, access to comprehensive care and less blame or shame around the condition. November 14, 2026 marks 135 years since Banting's birth.

An IDF release dated November 10, 2026 adds fresh evidence about barriers to testing. Its survey covered 2,411 adults aged 25–64 in six countries, all with type 2 diabetes risk factors and no diagnosis.

About four in ten respondents, 43%, said they wouldn't feel confident arranging a diabetes risk check. The samples weren't nationally representative, so that figure describes the surveyed group. It shows why a campaign about early action also needs to address how people reach care.

Insulin still has its own job

The new medicines have expanded the conversation about diabetes. Insulin remains essential: WHO explains that people with type 1 diabetes need insulin for survival.

Some people with type 2 diabetes also need insulin. Semaglutide and tirzepatide act through other hormone signals; neither supplies insulin.

For someone already prescribed semaglutide, that distinction matters when discussing what each medicine in their care plan does. An anniversary can recognize progress while keeping the different needs of people with diabetes in view.

What a prescription means today

Semaglutide and tirzepatide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications, which are different from FDA-approved products: the formulations offered here are not FDA-approved.

Compounding means preparing a medication for a particular prescription. FDA's compounding explanation states that the agency doesn't verify these preparations for safety, effectiveness or quality before marketing. The trials described above don't establish the results of a compounded preparation.

A licensed provider may still prescribe — that decision is between you and your doctor.

At Promise, a licensed provider reviews every request, and not everyone qualifies. That review considers the medical history, current medicines and reason for treatment.